RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: Immix Biopharma, Inc. has appointed Dr. Raymond Comenzo to its Nexcella Scientific Advisory Board to help advance CAR-T therapy aimed at treating AL Amyloidosis. Additionally, ResearchAndMarkets.com has published a report on four companies and their pipeline drugs, including Immuron's Phase II therapy for Traveler's Diarrhea, IMM-124E.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
